| 946 | 7 | 50 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：研究中药止痒平肤液对表皮生长因子受体抑制剂（epidermal growth factor receptor inhibitors;EGFRIs）相关皮损的疗效。方法：将BN大鼠分为空白组和吉非替尼组。空白组大鼠不给予干预；吉非替尼组大鼠予以吉非替尼灌胃给药，给药21 d。实验第22天，吉非替尼组大鼠再次进行分组，随机分为模型组、吉非替尼+外用止痒平肤液组、吉非替尼+外用生理盐水组，并继续予以吉非替尼灌胃；除空白组和模型组外，各组用不同的外用药物进行干预，连续给药7 d。动态观察实验过程中BN大鼠皮肤大体形态学变化、皮肤组织的病理变化。酶联免疫吸附试验检测大鼠血清中炎症因子TNF-α、IL-6的浓度。结果：外用药物干预7 d后，止痒平肤液组大鼠皮肤结痂、丘疹等表现明显减轻，且皮肤病理未看到明显炎症表现。在血清学炎症因子方面，止痒平肤液组TNF-α和IL-6浓度均显著低于模型组（P<0.05）；与空白组相比未见明显变化（P>0.05）。结论：中药止痒平肤液可明显减轻EGFRIs相关皮损，对于EGFRIs相关皮损具有较好的疗效。
Abstract：Objective:To explore the efficacy of Zhiyang Pingfu Liquid on the lesion associated with epidermal growth factor receptor inhibitors(EGFRIs). Methods:Female BN rats were divided into the control group and the gefitinib group,randomly. Rats in the gefitinib group were administered gefitinib for 21 d. After 21 d,the rats in the gefitinib group were randomly divided into the model group,the gefitinib+Zhiyang Pingfu Liquid group,and the gefitinib+normal saline group. From day 22,rats in the gefitinib+Zhiyang Pingfu Liquid or normal saline group were given Zhiyang Pingfu Liquid or normal saline for 7 d. The morphological changes and histopathological changes of the skin were observed. The changes of inflammatory factors such as TNF-αand IL-6 in the serum of were detected by ELISA. Results:The application of Zhiyang Pingfu Liquid for 7 d could significantly reduce the skin inflammation. The concentration of TNF-α and IL-6 in the gefitinib+Zhiyang Pingfu Liquid group was significantly lower than those in the model group(both P=0.002)and there were no significant changes compared with the control group(P>0.05). Conclusion:Zhiyang Pingfu Liquid can reduce the lesion and inflammation caused by EGFRIs.
1 Seto T,Kato T,Nishio M,et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567):An open-label,randomised,multicentre,phase 2 study[J].Lancet Oncol,2014,15(11):1236-1244.
2 Tan DS,Leighl NB,Riely GJ,et al.Safety and efficacy of nazartinib(EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma:A multicentre,open-label,phase 1 study[J].Lancet Respir Med,2020,8(6):561-572.
3 Kozuki T.Skin problems and EGFR-tyrosine kinase inhibitor[J].Jpn J Clin Oncol,2016,46(4):291-298.
4 Chiang TY,Hsu HC,Jane SW,et al.EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy[J].Support Care Cancer,2020,28(10):4771-4779.
5 Balagula Y,Garbe C,Myskowski PL,et al.Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors[J].Int JDermatol,2011,50(2):129-146.
6童莹慧，方罗，丁海樱，等.表皮生长因子受体抑制剂相关性皮肤毒性的研究进展[J].中国现代应用药学，2018,35(2):293-301.
7 Pasonen-seppanen S,Karvinen S,Torronen K,et al.EGF upregulates,whereas TGF-beta downregulates,the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures:Correlations with epidermal proliferation and differentiation[J].J Invest Dermatol,2003,120(6):1038-1044.
8 Petrelli F,Borgonovo K,Cabiddu M,et al.Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents:A systematic review and meta-analysis[J].Br J Dermatol,2016,175(6):1166-1174.
9 Lacouture ME,Mitchell EP,Piperdi B,et al.Skin toxicity evaluation protocol with panitumumab(STEPP),a phaseⅡ，open-label,randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer[J].J Clin Oncol,2010,28(8):1351-1357.
10 Yamada M,Iihara H,Fujii H,et al.Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients[J].Anticancer Res,2015,35(11):6175-6181.
11 Annunziata MC,De Stefano A,Fabbrocini G,et al.Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer[J].Clin Drug Investig,2019,39(9):825-834.
12胡洁，林丽珠，骆肖群，等.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志，2019,22(2):57-81.
13邓博，贾立群，崔慧娟，等.中药干预表皮生长因子受体抑制剂相关皮疹的荟萃分析[J].中日友好医院学报，2016,30(1):30-35.
14邓博，彭艳梅，崔慧娟，等.外用中药防治靶向药物皮肤毒性反应的网络药理分析[J].中华中医药学刊，2019,37(5):1054-1057.
15张心悦，彭艳梅，徐央波，等.肺腺癌患者应用表皮生长因子受体抑制剂治疗后皮肤不良反应的中医证候特点[J].中医杂志，2015,56(16):1401-1405.
16彭艳梅，崔慧娟，刘喆，等.止痒平肤液治疗表皮生长因子受体抑制剂相关皮肤不良反应的临床观察[J].中国中西医结合杂志，2017,37(2):149-154.
17郑舒月，崔慧娟，彭艳梅，等.基于数据挖掘的中药治疗表皮生长因子受体抑制剂相关皮疹的用药规律研究[J].中国医药导刊，2019,21(4):229-234.
18彭艳梅，刘青，邓博，等.表皮生长因子受体抑制剂致相关皮肤瘙痒的机制研究[J].中国比较医学杂志，2018,28(5):28-33.
19 Lacouture ME,Maitland ML,Segaert S,et al.A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group[J].Support Care Cancer,2010,18(4):509-522.
20 Sivaprasad U,Warrier MR,Gibson AM,et al.IL-13Ralpha2 has a protective role in a mouse model of cutaneous inflammation[J].J Immunol,2010,185(11):6802-6808.
21张旭，薛崇祥，李嘉，等.表皮生长因子受体抑制剂相关皮疹动物模型的构建[J].南方医科大学学报，2021,41(3):352-357.
22 Wan L,Wang Y,Tang Y,et al.Gefitinib-induced cutaneous toxicities in brown Norway rats are associated with macrophage infiltration[J].Inflammation,2020,43(6):2137-2146.
23 Surguladze D,Deevi D,Claros N,et al.Tumor necrosis factor-α and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice[J].Cancer Res,2009,69(14):5643-5647.
24 Mascia F,Lam G,Keith C,et al.Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy[J].Sci Transl Med,2013,5(199):199ra10.
25 Lichtenberger BM,Gerber PA,Holcmann M,et al.Epidermal EGFR controls cutaneous host defense and prevents inflammation[J].Sci Transl Med,2013,5(199):199ra11.
26 Liu Y,Jiang X,Gu Y,et al.Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor[J].Int Immunopharmacol,2019,69:79-87.
27 Ward NL,Bhagathavula N,Johnston A,et al.Erlotinibinduced skin inflammation is IL-1 mediated in KC-Tie2mice and human skin organ culture[J].J Invest Dermatol,2015,135(3):910-913.
28邹明，张红梅，徐艺筝，等.膝关节炎患者关节置换术后细菌感染严重程度与IL-1β、TNF-α、IL-6水平的相关性[J].中国微生态学杂志，2020,32(1):44-46.
29杨力夫，蔡晶娟，周晓玲，等.肺炎链球菌重症肺炎患儿血清超敏C反应蛋白、TNF-α、IL-6以及免疫球蛋白水平研究[J].传染病信息，2019,32(4):346-347,351.
30 Mascia F,Mariani V,Girolomoni G,et al.Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation[J].Am J Pathol,2003,163(1):303-312.
31 Ataie-kachoie P,Pourgholami MH,Richardson DR,et al.Gene of the month:Interleukin 6(IL-6)[J].J Clin Pathol,2014,67(11):932-937.
32 Taher MY,Davies DM,Maher J.The role of the interleukin(IL)-6/IL-6 receptor axis in cancer[J].Biochem Soc Trans,2018,46(6):1449-1462.
33张志成，廖玲.血清PCT和IL-6对重症急性胰腺炎继发感染的诊断价值[J].检验医学与临床，2015,12(19):2895-2896.
34马玲娣，朱志超，孙晓，等.IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用[J].中华血液学杂志，2015,36(5):422-426.
35刘晔，刘斌.苦参碱通过IL-6/STAT3信号通路抑制人结肠癌细胞[J].承德医学院学报，2021,38(2):100-102.
36张艳丽，王聪，朱雷蕾，等.黄芩苷药理作用研究进展[J].河南中医，2019,39(9):1450-1454.
37周晓鹰，陈洁，金柳，等.白鲜皮的药理作用及抗炎活性成分研究进展[J].常州大学学报（自然科学版），2018,30(1):82-86.
38黄小流，颜小星，张童童，等.马齿苋多糖对早期断奶大鼠生长性能、血清生化指标和肠道形态的影响[J].动物营养学报，2019,31(4):1773-1780.
39侯金佐，赵蕊，刘玉鹏，等.马齿苋黄酮类化合物的提取及活性研究综述[J].安徽农学通报，2019,25(1):30-33.
基本信息:
DOI：10.13210/j.cnki.jhmu.20220321.002
中图分类号:R285.5
引用信息:
[1]张旭,谭可欣,李嘉,等.止痒平肤液对表皮生长因子受体抑制剂相关皮损的治疗作用[J].海南医学院学报,2022,28(07):499-506.DOI:10.13210/j.cnki.jhmu.20220321.002.
基金信息:
国家自然科学基金项目资助（81873396）; 中日友好医院横向课题（2019-HX-69）~~
2022-03-22
2022-03-22
2022-03-22